The start of trials is a milestone for Bayer's ambition to develop cell and gene-based therapies for Parkinson's that could replace the dopamine-producing neurons in the midbrain area that are ...

Jeanne Kehren, head of digital and commercial innovation at Bayer, said: “Building new digital business models is a key element of our business strategy with the ambition to actively shape the ...